Suppr超能文献

直接报告药物不良反应对安全性监测过程的重要性。

The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process.

机构信息

Department of Management and Logistics in Healthcare, Medical University of Lodz, Lindleya Street 6, 90-131 Lodz, Poland.

Department of Epidemiology and Biostatistics, Medical University of Lodz, Żeligowskiego Street 7/9, 90-752 Lodz, Poland.

出版信息

Int J Environ Res Public Health. 2021 Dec 31;19(1):413. doi: 10.3390/ijerph19010413.

Abstract

All medicinal products authorized in the European Union are subjects of constant drug-safety monitoring processes. It is organized in a pharmacovigilance system that is designed to protect human health and life by the detection, analysis and prevention of adverse drug reactions (ADRs) and other drug-related problems. The main role of the aforementioned system is to collect and analyze adverse drug reaction reports. Legislation introduced several years ago allowed patients, their legal representatives and caregivers to report adverse drug reactions, which caused them to be an additional source of safety data. This paper presents the analysis of EudraVigilance data related to adverse drug reactions provided by patients, their representatives, as well as those obtained from healthcare professionals related to medicines which belong to M01A anti-inflammatory and antirheumatic products, a non-steroid group. The objective of the study was to identify the changes in the number and structure of adverse reaction reporting after the introduction of pharmacovigilance (PV) obligations in EU. A review of scientific literature was also conducted to assess the differences in adverse reactions reported by patients or their representatives and by healthcare professionals. We also identified other factors which, according to literature review, influenced the number of adverse reaction reports provided by patients. Analysis of data collected from the EudraVigilance showed that from 2011 to 2013 the number of reports made by patients and their caregivers increased by approx. 24 percentage points, and then, from 2014, it constituted around 30% of the total of reported reactions every year, so patient reporting is an important part of pharmacovigilance system and a source of drugs' safety information throughout their use in healthcare practice. Additionally, there was no interrelationship between the seriousness of reported adverse reactions and the overall number of patient reports when compared to reports form healthcare professionals.

摘要

所有在欧盟获得授权的药品都受到持续的药物安全监测过程的监管。这是通过药物警戒系统来组织的,旨在通过检测、分析和预防不良反应(ADR)和其他与药物相关的问题来保护人类健康和生命。上述系统的主要作用是收集和分析不良反应报告。几年前出台的立法允许患者、他们的法定代表人和护理人员报告不良反应,这使得他们成为安全数据的额外来源。本文分析了 EudraVigilance 中与患者、他们的代表以及与属于 M01A 类抗炎和抗风湿产品(非甾体类)的药物相关的医疗保健专业人员报告的不良反应相关的数据。该研究的目的是确定在欧盟引入药物警戒(PV)义务后,不良反应报告数量和结构的变化。还对科学文献进行了综述,以评估患者或其代表以及医疗保健专业人员报告的不良反应之间的差异。我们还确定了根据文献综述影响患者提供不良反应报告数量的其他因素。从 EudraVigilance 收集的数据分析表明,从 2011 年到 2013 年,患者及其护理人员的报告数量增加了约 24 个百分点,然后从 2014 年开始,每年约占报告反应总数的 30%,因此患者报告是药物警戒系统的重要组成部分,也是整个药物使用过程中药物安全性信息的来源。此外,与医疗保健专业人员的报告相比,报告的不良反应的严重程度与患者报告的总数之间没有相互关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8193/8745009/c7f18255902f/ijerph-19-00413-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验